Phase 1/2 MK-3120 trial of a selective receptor tyrosine kinase inhibitor.

This Phase 1/2, open-label trial conducted by Merck Sharp & Dohme LLC investigates the safety, dosing, and initial efficacy of MK-3120, a selective receptor tyrosine kinase inhibitor, in participants with advanced, unresectable solid tumors. The study employs two dosing arms to assess tolerability and anti-tumor activity, with participant assignment based on dose level; findings aim to guide optimal dose selection for future research on this investigational compound.